Frank E. Thomas has served as a member of the Larimar Therapeutics board of directors since May 2020, and prior to that, the Zafgen board of directors since June 2014. Mr. Thomas has been the Chief Operating Officer and Chief Financial Officer of Orchard Therapeutics since January 2020, a biotechnology company acquired by Kyowa Kirin in January 2024 with the goal of accelerating the delivery of new gene therapies to patients around the globe. Mr. Thomas served as Chief Financial Officer and Chief Business Officer of Orchard from January 2018 to January 2020. Prior to joining Orchard, Mr. Thomas served as President and Chief Operating Officer of AMAG Pharmaceuticals, Inc., a publicly traded, specialty pharmaceutical company, from 2015 to 2017, and previously served as AMAG’s Executive Vice President and Chief Operating Officer from 2012 through 2015 and as Executive Vice President, Chief Financial Officer and Treasurer from 2011 through 2012. Prior to joining AMAG, he served in executive roles at Molecular Biometrics, Inc., a commercial stage medical diagnostics company, from 2008 to 2011, Critical Therapeutics, Inc., a public biopharmaceutical company, from 2004 to 2008, and Esperion Therapeutics, Inc., a public biopharmaceutical company from 2000 to 2004. Mr. Thomas served as Chief Executive Officer and a member of the board of directors of Critical Therapeutics from 2006 to 2008. Since July 2017, Mr. Thomas has served on the board of directors of Spero Therapeutics, Inc., a publicly traded, development-stage biotechnology company. Mr. Thomas was a member of the board of directors of the Massachusetts Biotechnology Council from 2007 to 2015. Mr. Thomas holds a B.B.A. from the University of Michigan, Ann Arbor.
